Back to results
US 5,726,166 AGranted
Malaria treatments
AssigneeBritish Technology Group Limited
InventorsJohn Hugh Lyon Playfair, Janice Taverne, Clive Alan Winston Bate
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBritish Technology Group Limited
InventorsJohn Hugh Lyon Playfair, Janice Taverne, Clive Alan Winston Bate
Estimating the term…
A method of treating or preventing clinical manifestations associated with diseases caused by infectious organisms which express antigens which in the patient stimulate secretion of harmful levels of at least one cytokine, other than diseases caused by organisms which stimulate secretion of cytokines only by expression of lipopolysaccharide, which method comprises administering to a human in need thereof an effective non-toxic amount of a material selected from the group consisting of inhibitors and immunogens wherein said inhibitors are pharmacologically acceptable materials which, in vitro, reduce or abolish secretion, by at least one of human monocytes and mouse peritoneal macrophages, of tumour necrosis factor following stimulation with a phospholipid-containing; tumour necrosis factor-inducing antigen other than lipopolysaccharide, and wherein said immunogens are pharmacologically acceptable materials comprising at least one B-cell epitope and which stimulate production of antibodies which, in vitro, reduce or abolish secretion, by at least one of human monocytes and mouse peritoneal macrophages, of tumour necrosis factor following stimulation with a phospolipid-containing, tumour necrosis factor-inducing antigen other than lipopolysaccharide. Examples of inhibitors include inositol monophosphate and phosphatidyl inositol lipids. Immunogens include these inhibitors optionally with carrier proteins.
A method of treating or preventing clinical manifestations of malaria, caused by infectious plasmodial organisms which express antigens which in the patient stimulate secretion of harmful levels of at least one cytokine, but which do not stimulate secretion of cytokines only by expression of lipopolysaccharide, which method comprises administering to a human in need thereof an effective non-toxic amount of an immunogen, wherein said immunogen is a pharmacologically acceptable material comprising inositol monophosphate or a phosphatidyl inositol, which immunogen stimulates production of antibodies which, in vitro, reduce or abolish secretion, by at least one of human monocytes and mouse peritoneal macrophages, of tumour necrosis factor following stimulation with a phospholipid-containing tumour necrosis factor-inducting antigen other than lipopolysaccharide.
A material for use in the treatment or prevention of clinical manifestations of malaria, caused by infectious plasmodial organisms which express antigens which in the patient stimulate secretion of harmful levels of at least one cytokine, but which do not stimulate secretion of cytokines only by expression of lipopolysaccharide, which material is an immunogen, wherein said immunogen is a pharmacologically acceptable material comprising inositol monophosphate or a phosphatidyl inositol, which immunogen stimulates production of antibodies which, in vitro reduce or abolish secretion, by at least one human monocytes and mouse peritoneal macrophages, of tumour necrosis factor following stimulation with a phospholipid-containing, tumour necrosis factor-inducing antigen other than lipopolysaccharide.
Dependencies are inferred from the claim text.